Your SlideShare is downloading. ×
0
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

BIOTECHNOLOGY IN THE NEW EU MEMBER STATES: AN EMERGING SECTOR

199

Published on

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
199
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. What can Polish Biotechnology offer to Western Industry Kasia Galecka Venture Valuation June 2010
  • 2. About Us Independent assessment and valuation of high growth firms prior to an investment, trade sale or licensing deal. Life Science company database including product, technology and licensing deal information about over 18’000 companies world wide. European Commission sponsored project to assess the state of the biotechnology industry in the 14 New Member and Candidate States. In Collaboration with EuropaBIO.
  • 3. Overview 1) A Developing Sector: Poland and the 14 New EU Member States Status of the Sector Finding Unmet Need 2) Attracting Investment The Funding Cycle Public Funding Private Funding CROs
  • 4. A Developing Sector: Poland and the 14 New Member States 0 10 20 30 40 50 60 DCI Quantitative Factor Total Qualitative Factor Total DCIin the 14 new Member Sates and Candidate Countries Development Capacity Index (DCI) “A higher DCI indicates the presence of a more advanced biotechnology industry and a more favourable environment for future growth” Source: Biotech in the New Member States: An Emerging Sector
  • 5. A Developing Sector: Status of the Sector Poland 14 New Members Switzerland 59 274 285 Total BiotechnologyCompanies 4 20 71 Biotech- Therapeutics 35 178 164 Biotech- R&DServices 20 76 50 Biotech- Other >3'500 >10'000 >19'000 Employees >250 >1'900 >1'000 R&DEmployees 86% 89% 90% Percentageof SME's 2% 2% 5% Percentageof Companies PubliclyOwned
  • 6. A Developing Sector: Composition of the Biotechnology Industry 0% 10% 20% 30% 40% 50% CRO/ CMO Other Services Therapeutics Other Biotech Poland 14New EUMembers Switzerland Source: www.biotechgate.com
  • 7. A Developing Sector: Stage of the Biotech Pipeline 0 50 100 Discovery &Preclinical PhaseI PhaseII PhaseIII Poland 14New EUMembers Switzerland Source: www.biotechgate.com
  • 8. Attracting Investment: Finding Unmet Need 0% 5% 10% 15% 20% 25% 30% 35% Metabolic disorders Respiratory Infectious diseases Nervous system Cardiovascular Skinand subcutaneous tissue Diseases of the eye Genitourinary system Digestive system Oncology Mental disorders Musculoskeletal system Blood and immuned disorders Out-Licensing Opportunities Products Under Development Source: www.biotechgate.com
  • 9. Attracting Investment: The Funding Cycle BASIC RESEARCH BASIC RESEARCH SEED STAGESEED STAGE START-UP STAGE START-UP STAGE FIRST STAGE (Phase I) FIRST STAGE (Phase I) SECOND STAGE (Phase II) SECOND STAGE (Phase II) LATER STAGE (Phase III) LATER STAGE (Phase III) MARKET STAGE MARKET STAGE Founders & Friends Business Angels Venture Capital Licensing Deals IPO / Trade Sale Public / EU Funding
  • 10. Attracting Investment: Public Funding FP7 - Total budget for 2007-2013: approx. € 54 Billion - Top down approach (specific calls for proposals) - Large consortia (3-20 participants) - Funding is 75% for SME - Competition is high, typical chances of success: 10-20% - Typical amount of funding for a participant is around € 100‘000 / year EUREKA / Eurostars, ERASMUS, IMI Source: KAPPA-Health Training Materials
  • 11. Attracting Investment: Private Funding Founders & Friends - no dilution of profits or risk - limited growth potential - no dependencies Business Angels - hard to find - finance small amounts and often demand large price per share - can provide a network and operational support Venture Capital - take high risks and expect high returns - plan specific exits - responsible to their own investors
  • 12. Attracting Investment: Private Funding Licensing Deal - share development risks and rewards - milestone and royalty payments - no dependencies Trade Sale - convenient exit for investors - price greatly affected by market and firm stage IPO - cheaper access to capital - minimum market cap and other requirements - timing is crucial
  • 13. Attracting Investment: Example: Evolva Seed Stage Asset Acquisition from Poalis S/A US Defence Contract / Functional Genetics Cappella FP6 EU Project ARO and USAMRIID Contracts Phase I / Divinocell FP7 EU Project Roche June 2004 2005 2006 2007 2010 Seed funding from 3 early stage VCs CHF 21.8 m Series A Awarded USD 26.7 m for drug development programs CHF 12 m second round investment 2008 2009 Funding award from Global Cardiovascular Innovation Centre CHF 28 m first round series B CHF 16 m second round series B Reverse merge listed on SIX Discovery and development of novel, differentiated pharmaceutical product candidates that target significant unmet medical needs, with an emphasis on cardio-renal and infectious diseases.
  • 14. Attracting Investment: Private Funding – Venture Capital and Poland National Investment - Polish Private Equity Association - most active equity and VC investment of the new member states Foreign Investors - becoming more aware of investment opportunities in Poland - hesitant to invest in areas where they do not have expertise or a good network - need to be attracted by something special they cannot get locally - wait for local venture capital community to be established first as a validation - sceptical of government supported venture capital efforts - a critical mass of companies needs to be achieved to attract foreign investors
  • 15. Attracting Investment: The Importance of CROs and Service Companies - Leverage the highly skilled and price competitive work force - Attract potential partners and clients to the area - Revenues generated by services can be used to finance product development
  • 16. Thank you for your attention Kasia Galecka Venture Valuation AG Kasernenstrasse 11 8004 Zürich Switzerland k.galecka@venturevaluation.com +41 43 321 8660 Slides available at www.venturevaluation.com www.venturevaluation.com www.biotechgate.com www.polishbiotech.com

×